Aprea Therapeutics, Inc. APRE · Stock Open Aprea Therapeutics, Inc. in new tab
Aprea Therapeutics, Inc. Analysis (APRE)
Is Aprea Therapeutics, Inc. a good investment? Aprea Therapeutics, Inc. (APRE) is currently trading at 0.7095 USD. Market analysts have a consensus price target of 4.30 USD. This suggests a potential upside from current levels.
Earnings Schedule: Aprea Therapeutics, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.79.
Investor FAQ
Does Aprea Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Aprea Therapeutics, Inc.?
Aprea Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.49.
Company Profile
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 13, 2023 | 0.050000 |
Community Discussion